Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been ...

Icon's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. Icon has historically maintained a fairly conservative balance sheet, and it ended ...

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...

NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and ...

The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint ...

Austin's status as an emerging hub for life sciences is of particular importance now, because the momentum is expected to help blunt the impact of potentially millions annually in cuts to federal ...

Explore key insights from ICON's Q4 2024 earnings call, including bookings growth, digital innovation, and strategic partnerships driving 2025 growth targets.

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

The Janus Henderson Global Sustainable Equity Fund returned -5.88% for Q4 2024. Click here to read the full commentary.

ICON Plc 's stock (NASDAQ:ICLR) has reached a 52-week low, dipping to $183.31, as the company navigates through a turbulent market environment. With a market capitalization of $15.19 billion and a P/E ...